跳至主要内容
临床试验/NCT01692665
NCT01692665撤回不适用

Changes of Keratometric Value and Ocular Aberration After Treatment of Meibomian Gland Dysfunction

Yonsei University0 个研究点开始时间: 2012年11月最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
主要终点
Changes of keratometric value and ocular aberration

研究概览

简要总结

Ocular aberration may play a role in determining optical quality. Recently performed study reported that ocular aberration of preocular tear film would be important factor in not only diagnosing the dry eye but also determining the efficacy of treatment. Therefore, in this study, the investigators will aim to prove the improvement of quality of vision via ocular aberration changes indirectly after the proper treatment for moderate and severe meibomian gland dysfunction. Also, the investigators will evaluate the changes of keratometric values after treatment for moderate and severe meibomian gland dysfunction, which could be demonstrated by autokeratometry, IOLMaster, Pentacam, and iTrace.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
20 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • (1) stage 3 or 4 meibomian gland dysfunction

排除标准

  • history of previous ocular or intraocular surgery
  • ocular infection, non dry eye ocular inflammation, ocular allergy, autoimmune disease,
  • history of intolerance or hypersensitivity to any component of the study medications,
  • wearing contact lenses during the study period, presence of current punctal occlusion,
  • pregnancy, lactating women, and children.
  • Additionally, patients were excluded if they were using any topical ocular or systemic medication that could be used for the treatment MGD or dry eye, including topical or oral antibiotics, topical cyclosporine A, topical or oral steroids, topical non-steroidal anti-inflammatory drugs, topical ocular allergy medications or artificial tears

结局指标

主要结局

Changes of keratometric value and ocular aberration

时间窗: a minimum of four minutes, once or twice dailybefore treatment, after 1 month, and after 2 months of treatment

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

相似试验